Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sinocelltech GroupSHSE:688520 -2.41%54 Altman Z-Score is 1.03 as of Jul. 23, 2026, which is 61% below its 10-year median of 2.63. GuruFocus rates SHSE:688520 with a GF Score™ of 54/100 and a GF Value™ of ¥36.51 (Fairly Valued). The stock has 6 warning signs investors should review. Among 927 Biotechnology companies, Sinocelltech Group ranks worse than 59.65% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Warning Sign:
Altman Z-score of 1.11 is in distress zone. This implies bankruptcy possibility in the next two years.
Sinocelltech Group has a Altman Z-Score of 1.03, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Sinocelltech Group's Altman Z-Score or its related term are showing as below:
SHSE:688520'
s Altman Z-Score Range Over the Past 10 Years
Min: 1.11 Med: 2.63 Max: 18.24
Current: 1.11
During the past 10 years, Sinocelltech Group's highest Altman Z-Score was 18.24. The lowest was 1.11. And the median was 2.63.
Sinocelltech Group (SHSE:688520) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Sinocelltech Group Altman Z-Score Related Terms
Sinocelltech Group Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Sinocelltech Group's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688520 vs VRTX, REGN, ALNY: Altman Z-Score Comparison
For the Biotechnology subindustry, Sinocelltech Group's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinocelltech Group Altman Z-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sinocelltech Group's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Sinocelltech Group's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Sinocelltech Group's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
-0.0116
+
1.4
*
-1.0118
+
3.3
*
-0.1598
+
0.6
*
4.4783
+
1.0
*
0.3007
=
1.03
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Sinocelltech Group (SHSE:688520) has a Altman Z-Score of 1.03 as of Jul. 23, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Sinocelltech Group and its competitors. This is 61% below median its historical median of 2.63. Over the past decade, Sinocelltech Group's Altman Z-Score has ranged from 1.11 to 18.24. According to the industry distribution chart, Sinocelltech Group ranks #553 out of 927 companies in the Biotechnology industry, placing it in the top 59.7%.
Is Sinocelltech Group's Altman Z-Score too high?
Sinocelltech Group's current Altman Z-Score of 1.03 is 61% below median its 10-year median of 2.63. Over the past 10 years, this metric has ranged from a low of 1.11 to a high of 18.24. The Biotechnology industry median Altman Z-Score is 2.57. Sinocelltech Group's value of 1.03 is 59.9% below this industry median. Based on the distribution chart, Sinocelltech Group ranks #553 out of 927 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Sinocelltech Group has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sinocelltech Group's Altman Z-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sinocelltech Group ranks #553 out of 927 companies for Altman Z-Score. This places Sinocelltech Group in the lower half of its industry. The industry median Altman Z-Score is 2.57. Sinocelltech Group's value of 1.03 is 59.9% below this benchmark. Historically, Sinocelltech Group's own Altman Z-Score has ranged from 1.11 to 18.24 over the past decade. While the company's 10-year median is 2.63 vs. the industry median of 2.57, Sinocelltech Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.57, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinocelltech Group's current Altman Z-Score of 1.03 is 59.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Sinocelltech Group and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinocelltech Group's current Altman Z-Score is 1.03, which is 61% below median its own 10-year median of 2.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinocelltech Group stock overvalued right now?
Based on GuruFocus' analysis, Sinocelltech Group (SHSE:688520) is currently considered Fairly Valued. The stock's GF Value™ is ¥36.51, compared to a current price of ¥35.23 — trading 3.5% below its estimated fair value. The current Altman Z-Score is 1.03, which is 61% below median its 10-year median of 2.63 and 59.9% below the Biotechnology industry median of 2.57. Sinocelltech Group's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Sinocelltech Group (SHSE:688520), the current Altman Z-Score is 1.03 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinocelltech Group (SHSE:688520) Overvalued in 2026?
Based on GuruFocus' analysis, Sinocelltech Group stock appears to be undervalued.
The current stock price of ¥35.23 is trading 3.5% below its estimated GF Value™ of ¥36.51.
GuruFocus considers Sinocelltech Group to be Fairly Valued.
Key valuation signals for SHSE:688520:
Altman Z-Score: 1.03 (61% below median its 10-year median of 2.63)
GF Value™: ¥36.51 vs. price of ¥35.23 (3.5% below fair value)
Industry Position: 59.9% below the Biotechnology median (#553 of 927)
No single metric tells the full story. See the SHSE:688520 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sinocelltech Group Ltd is one of Chin's biopharma companies specializing in biologics and vaccines. The company's therapeutic areas include oncology, immunology and inflammation, ophthalmology, and prophylactic vaccines. The company has developed technology platforms in protein expression vectors, cell line development, serum-free medium development, stoichiometrically controlled fed-batch cell culture, process scale-up, and protein purification. The capabilities of the company include stable CHO cell line development, cell banking and certification, serum-free and protein-free culture medium development, fed-batch cell culture process development, optimization, and process scale-up, protein purification development, and large scale production.
54GF Score
Get the complete analysis for SHSE:688520
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688520 has been successfully added to your 
